Health

Add as a preferred source on Google

Servier Reports 37.2-Month PFS in Vorasidenib Glioma Crossover Analysis

A separate seizure analysis produced different rate estimates in a Servier presentation and a 2026 journal abstract.

Updated 2 min read
Attendees listen during a neuro-oncology session at the Society for Neuro-Oncology meeting in Philadelphia. (AI-generated image / EconoTimes)
Attendees listen during a neuro-oncology session at the Society for Neuro-Oncology meeting in Philadelphia. (AI-generated image / EconoTimes)

Servier reported a 37.2-month median progression-free survival in patients who crossed from placebo to vorasidenib in the INDIGO glioma trial, adding follow-up information on a treatment approved in the United States for certain tumors after surgery.

The Phase 3 trial enrolled 331 patients with Grade 2 IDH-mutant glioma after surgery and assigned them to vorasidenib or placebo. By the Jan. 17, 2025, data cutoff, 144 of the 163 patients initially assigned to placebo had switched to vorasidenib.

Servier gave the crossover group a median investigator-assessed progression-free survival of 37.2 months. The figure was also 37.2 months among patients with astrocytoma; the median had not been reached for those with oligodendroglioma. Among patients whose disease had progressed by the switch, the reported median was 33.4 months, while it had not been reached among those without progression.

A post hoc review of tumor measurements found that average tumor volume grew by 16.1% per six-month period before patients switched and fell by 2.9% per six-month period afterward. Servier reported the pattern in both tumor subtypes. These results follow patients after their treatment changed and do not provide a randomized comparison with patients continuing on placebo.

At the Society for Neuro-Oncology’s 2026 annual meeting in Philadelphia, Servier presented the crossover findings Saturday, Nov. 14, and separate exploratory seizure and quality-of-life results Sunday, Nov. 15. For the seizure analysis, Servier reported a rate of 18.2 per person-year in March 2023 and 15.9 in January 2025; the rate ratio against placebo moved from 0.36 to 0.28.

A 2026 Journal of Clinical Oncology abstract using the Jan. 17, 2025, cutoff instead reported 13.2 seizures per person-year for vorasidenib and a 0.20 rate ratio against placebo. The reports did not give a reason for the difference. The journal abstract said its seizure analyses were exploratory, not prespecified and not adjusted for multiplicity.

Among patients with more than one seizure, Servier also reported lower risks of worsening versus placebo on the Functional Assessment of Cancer Therapy–Brain scale and its brain cancer subscale. The reported hazard ratios were 0.38 and 0.32, respectively.

The Food and Drug Administration approved vorasidenib on Aug. 6, 2024, for adults and children 12 and older with Grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation after surgery.

Related articles

View all
Business

Profiling Brain Cancers for More Targeted Treatments

Farmington, Conn., Dec. 22, 2017 -- Roel Verhaak, Ph.D., is not beholden to the status quo. After all, his field, computational biology, didn’t exist, at least not formally, when he began his post-secondary studies. He q…